SHARE:
FacebookTwitterFacebookPrintShare

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension

Systematic Review ARCHIVED Nov 1, 2007

Related Files

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Archived: This report has been updated.

Excerpt

In this comparative effectiveness review, we examine the scientific literature on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs, or angiotensin receptor blockers) for individuals with hypertension regarding their relative benefits (blood pressure control, cardiovascular risk reduction, cardiovascular events, quality of life, and other outcomes), as well as relative risks (safety, adverse events, tolerability, persistence, and adherence). In addition, we will examine the clinical determinants of these outcomes with a focus on the long-term impact.

Project Timeline

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension

Jan 1, 2005
Topic Initiated
Nov 1, 2007
Systematic Review Archived
Page last reviewed December 2019
Page originally created November 2017

Internet Citation: Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.
https://effectivehealthcare.ahrq.gov/products/ace-inhibitor-arb-2007/research-2007-1

Select to copy citation